These findings collectively nominate ZFAS1 as a therapeutically actionable master regulator of sorafenib resistance in HCC, presenting a promising RNA-targeted strategy to circumvent therapeutic failure [57]. This evidence concerns the gene ZFAS1 and hepatocellular carcinoma.